Product Lawsuits Sources
The federal multidistrict litigation records, the drug safety notices, the asbestos trusts and the state deadlines for a drug injury.
198 documents · 845 records
Multidistrict litigation court records
45 documents · 201 records
- Amended Case Management Order No. 3, In re Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, MDL No. 3092, No. 1:24-md-3092, ECF No. 165, at 2 (N.D. Ohio Nov. 22, 2024)ohnd.uscourts.gov · Last read Oct. 6, 2026
- Case Management Order No. 12, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 701, at 2 (N.D. Fla. July 27, 2026)govinfo.gov · Last read Oct. 6, 2026
- Case Management Order No. 12, In re Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, MDL No. 3092, No. 1:24-md-3092, ECF No. 158, at 1 (N.D. Ohio Nov. 4, 2024)ohnd.uscourts.gov · Last read Oct. 6, 2026
- Case Management Order No. 13, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 711, at 1 (N.D. Fla. Aug. 5, 2026)flnd.uscourts.gov · Last read Oct. 6, 2026
- Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 2 (N.D. Fla. Aug. 10, 2026)flnd.uscourts.gov · Last read Oct. 6, 2026
- Case Management Order No. 20, In re Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, MDL No. 3092, No. 1:24-md-3092, ECF No. 520, at 1 (N.D. Ohio Oct. 8, 2025)ohnd.uscourts.gov · Last read Oct. 6, 2026
- Case Management Order No. 23, In re Paraquat Products Liability Litigation, MDL No. 3004, No. 3:21-md-3004-NJR, ECF No. 5783, at 2 (S.D. Ill. Feb. 11, 2026)ilsd.uscourts.gov · Last read Oct. 6, 2026
- Case Management Order No. 24, In re Paraquat Products Liability Litigation, MDL No. 3004, No. 3:21-md-3004-NJR, ECF No. 5808, at 1 (S.D. Ill. Apr. 8, 2026)ilsd.uscourts.gov · Last read Oct. 6, 2026
- Case Management Order No. 33, In re Aqueous Film-Forming Foams Products Liability Litigation, MDL No. 2873, No. 2:18-mn-2873-RMG, ECF No. 6863, at 2 (D.S.C. Mar. 26, 2025)scd.uscourts.gov · Last read Oct. 6, 2026
- Case Management Order No. 33F, In re Aqueous Film-Forming Foams Products Liability Litigation, MDL No. 2873, No. 2:18-mn-2873-RMG, ECF No. 11298, at 1 (D.S.C. Aug. 31, 2026)scd.uscourts.gov · Last read Oct. 6, 2026
- Case Management Order No. 35, In re Aqueous Film-Forming Foams Products Liability Litigation, MDL No. 2873, No. 2:18-mn-2873-RMG, ECF No. 7823, at 1 (D.S.C. Aug. 15, 2025)scd.uscourts.gov · Last read Oct. 6, 2026
- Hardeman v. Monsanto Co., No. 19-16636, slip op. at 7 (9th Cir. May 14, 2021)cdn.ca9.uscourts.gov · Last read Oct. 6, 2026
- In re Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation, MDL No. 3060, No. 1:23-cv-00818, Doc. 291, at 1 (N.D. Ill. Nov. 13, 2023)govinfo.gov · Last read Oct. 6, 2026
- J.P.M.L., MDL Statistics Report, Distribution of Pending MDL Dockets by Actions Pending (report date Oct. 1, 2026)jpml.uscourts.gov · Last read Oct. 6, 2026
- J.P.M.L., MDL Statistics Report, Docket Summary Listing (report date Oct. 1, 2026)jpml.uscourts.gov · Last read Oct. 6, 2026
- Judgment (WHB 823), In re Uber Technologies, Inc., Passenger Sexual Assault Litigation, MDL No. 3084, No. 3:23-md-3084-CRB, ECF No. 5932, at 2 (N.D. Cal. Apr. 20, 2026)govinfo.gov · Last read Oct. 6, 2026
- Judgment, In re Uber Technologies, Inc., Passenger Sexual Assault Litigation, MDL No. 3084, No. 3:23-md-3084-CRB, ECF No. 5203, at 1 (N.D. Cal. Feb. 6, 2026)govinfo.gov · Last read Oct. 6, 2026
- Memorandum and Order, In re Paraquat Products Liability Litigation, MDL No. 3004, No. 3:21-md-3004-NJR, ECF No. 5237, at 1 (S.D. Ill. Apr. 17, 2024)ilsd.uscourts.gov · Last read Oct. 6, 2026
- Memorandum and Order, In re Paraquat Products Liability Litigation, MDL No. 3004, No. 3:21-md-3004-NJR, ECF No. 5238, at 3 (S.D. Ill. Apr. 17, 2024)ilsd.uscourts.gov · Last read Oct. 6, 2026
- Monsanto Co. v. Durnell, 609 U.S. 371, 373 (2026)supremecourt.gov · Last read Oct. 6, 2026
- Opinion and Order, In re Acetaminophen - ASD-ADHD Products Liability Litigation, MDL No. 3043, No. 1:22-md-3043-DLC, ECF No. 1381, at 5 (S.D.N.Y. Dec. 18, 2023)nysd.uscourts.gov · Last read Oct. 6, 2026
- Opinion and Order, In re Acetaminophen - ASD-ADHD Products Liability Litigation, MDL No. 3043, No. 1:22-md-3043-DLC, ECF No. 1494, at 3 (S.D.N.Y. July 10, 2024)nysd.uscourts.gov · Last read Oct. 6, 2026
- Opinion and Order, In re Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, MDL No. 3092, No. 1:24-md-3092, ECF No. 173, at 33 (N.D. Ohio Dec. 31, 2024)ohnd.uscourts.gov · Last read Oct. 6, 2026
- Order Adopting Special Master's Report and Recommendations, In re Paraquat Products Liability Litigation, MDL No. 3004, No. 3:21-md-3004-NJR, ECF No. 5839, at 1 (S.D. Ill. June 10, 2026)ilsd.uscourts.gov · Last read Oct. 6, 2026
- Order Extending Stay (text order), In re Paraquat Products Liability Litigation, MDL No. 3004, No. 3:21-md-3004-NJR (S.D. Ill. Dec. 30, 2025)ilsd.uscourts.gov · Last read Oct. 6, 2026
- Order Extending Stay and Vacating Trial Date, In re Paraquat Products Liability Litigation, MDL No. 3004, No. 3:21-md-3004-NJR, ECF No. 5719, at 1 (S.D. Ill. Sept. 29, 2025)ilsd.uscourts.gov · Last read Oct. 6, 2026
- Order Selecting Opt-Out Cases for Limited Discovery, In re Paraquat Products Liability Litigation, MDL No. 3004, No. 3:21-md-3004-NJR, ECF No. 5833, at 1 (S.D. Ill. June 2, 2026)ilsd.uscourts.gov · Last read Oct. 6, 2026
- Pretrial Order No. 10, In re Uber Technologies, Inc., Passenger Sexual Assault Litigation, MDL No. 3084, No. 3:23-md-3084-CRB, ECF No. 348, at 3 (N.D. Cal. Mar. 19, 2024)govinfo.gov · Last read Oct. 6, 2026
- Pretrial Order No. 17, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 178, at 1 (N.D. Fla. Mar. 14, 2025)govinfo.gov · Last read Oct. 6, 2026
- Pretrial Order No. 30, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 534, at 3 (N.D. Fla. Jan. 27, 2026)govinfo.gov · Last read Oct. 6, 2026
- Pretrial Order No. 42, In re Uber Technologies, Inc., Passenger Sexual Assault Litigation, MDL No. 3084, No. 3:23-md-3084-CRB, ECF No. 5670, at 1 (N.D. Cal. Mar. 27, 2026)govinfo.gov · Last read Oct. 6, 2026
- Pretrial Order No. 81, In re Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924, No. 9:20-md-2924-RLR, ECF No. 6271 (S.D. Fla. Feb. 14, 2023)flsd.uscourts.gov · Last read Oct. 6, 2026
- Pretrial Order No. 84, In re Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924, No. 9:20-md-2924-RLR, ECF No. 6923 (S.D. Fla. Aug. 21, 2023)flsd.uscourts.gov · Last read Oct. 6, 2026
- Second Amended Case Management Order No. 15, In re Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, MDL No. 3092, No. 1:24-md-3092, ECF No. 668, at 27 (N.D. Ohio Mar. 27, 2026)ohnd.uscourts.gov · Last read Oct. 6, 2026
- Second Amended Case Management Order No. 28, In re Aqueous Film-Forming Foams Products Liability Litigation, MDL No. 2873, No. 2:18-mn-2873-RMG, ECF No. 4985, at 4 (D.S.C. May 15, 2024)scd.uscourts.gov · Last read Oct. 6, 2026
- Supreme Court of the United States, Docket No. 24-1068 (read Oct. 6, 2026)supremecourt.gov · Last read Oct. 6, 2026
- Tentative Ruling Entering Rule 58 Final Judgment, In re Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924, No. 9:20-md-2924-RLR, ECF No. 6787, at 1 (S.D. Fla. July 21, 2023)flsd.uscourts.gov · Last read Oct. 6, 2026
- Transfer Order (J.P.M.L.), In re Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, MDL No. 3092, No. 1:24-md-3092, ECF No. 1, at 1 (N.D. Ohio filed Feb. 5, 2024)ohnd.uscourts.gov · Last read Oct. 6, 2026
- U.S. District Court for the District of South Carolina, MDL No. 2873 website, Introduction (read Oct. 6, 2026)scd.uscourts.gov · Last read Oct. 6, 2026
- U.S. District Court for the Northern District of California, case page for MDL No. 3084 (read Oct. 6, 2026)cand.uscourts.gov · Last read Oct. 6, 2026
- U.S. District Court for the Northern District of Florida, MDL No. 3140 website, Orders By Date (read Oct. 6, 2026)flnd.uscourts.gov · Last read Oct. 6, 2026
- U.S. District Court for the Northern District of Ohio, MDL 3092 website (read Oct. 6, 2026)ohnd.uscourts.gov · Last read Oct. 6, 2026
- U.S. District Court for the Southern District of Florida, MDL No. 2924 website (read Oct. 6, 2026)flsd.uscourts.gov · Last read Oct. 6, 2026
- U.S. District Court for the Southern District of Illinois, Paraquat Products Liability Litigation website (read Oct. 6, 2026)ilsd.uscourts.gov · Last read Oct. 6, 2026
- U.S. District Court for the Southern District of New York, MDL No. 3043 website (read Oct. 6, 2026)nysd.uscourts.gov · Last read Oct. 6, 2026
GLP-1 litigation: the court record
20 documents · 74 records
- Amended Case Management Order No. 12 (Plaintiff Fact Sheets), No. 24-md-3094, Doc. 656 (E.D. Pa. filed Apr. 30, 2026)paed.uscourts.gov · Last read Sept. 26, 2026
- Case Management Order No. 4 (Direct Filing Order), No. 25-md-3163, Doc. 25 (E.D. Pa. filed Jan. 29, 2026)paed.uscourts.gov · Last read Sept. 26, 2026
- Case Management Order No. 12 (Plaintiff Fact Sheets), No. 24-md-3094, Doc. 188, with Exhibit A, the Plaintiff Fact Sheet, Doc. 188-1 (E.D. Pa. filed July 14, 2024)paed.uscourts.gov · Last read Sept. 26, 2026
- Case Management Order No. 14 (Direct Filing Order), No. 24-md-3094, Doc. 190 (E.D. Pa. filed July 14, 2024)paed.uscourts.gov · Last read Sept. 26, 2026
- Case Management Order No. 27 (Short Form Complaint Enabling Order), No. 24-md-3094, Doc. 503, with Exhibit 1, the Short Form Complaint, Doc. 503-1 (E.D. Pa. filed Oct. 3, 2025)paed.uscourts.gov · Last read Sept. 26, 2026
- Drugs@FDA overview page for application 022341, U.S. Food and Drug Administration, read Sept. 26, 2026accessdata.fda.gov · Last read Sept. 26, 2026
- Drugs@FDA overview page for application 125469, U.S. Food and Drug Administration, read Sept. 26, 2026accessdata.fda.gov · Last read Sept. 26, 2026
- Drugs@FDA overview page for application 206321, U.S. Food and Drug Administration, read Sept. 26, 2026accessdata.fda.gov · Last read Sept. 26, 2026
- Drugs@FDA overview page for application 209637, U.S. Food and Drug Administration, read Sept. 26, 2026accessdata.fda.gov · Last read Sept. 26, 2026
- Drugs@FDA overview page for application 213182, U.S. Food and Drug Administration, read Sept. 26, 2026accessdata.fda.gov · Last read Sept. 26, 2026
- Drugs@FDA overview page for application 215256, U.S. Food and Drug Administration, read Sept. 26, 2026accessdata.fda.gov · Last read Sept. 26, 2026
- Drugs@FDA overview page for application 215866, U.S. Food and Drug Administration, read Sept. 26, 2026accessdata.fda.gov · Last read Sept. 26, 2026
- Drugs@FDA overview page for application 217806, U.S. Food and Drug Administration, read Sept. 26, 2026accessdata.fda.gov · Last read Sept. 26, 2026
- Memorandum, In re GLP-1 RAs Prods. Liab. Litig., No. 24-md-3094, Doc. 465 (E.D. Pa. filed Aug. 15, 2025)govinfo.gov · Last read Sept. 26, 2026
- Novo Nordisk A/S, Annual Report 2025, filed with the U.S. Securities and Exchange Commission as an exhibit to its Form 20-F for 2025 (EDGAR accession 0000353278-26-000012), Note 3.6, Provisions and contingent liabilitiessec.gov · Last read Sept. 26, 2026
- Order Denying Transfer, In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094, Doc. 273 (J.P.M.L. filed Dec. 12, 2024)jpml.uscourts.gov · Last read Sept. 26, 2026
- Order, In re GLP-1 RAs Prods. Liab. Litig., No. 24-md-3094, Doc. 466 (E.D. Pa. filed Aug. 15, 2025)govinfo.gov · Last read Sept. 26, 2026
- Order, In re GLP-1 RAs Prods. Liab. Litig., No. 24-md-3094, Doc. 468 (E.D. Pa. filed Aug. 15, 2025)govinfo.gov · Last read Sept. 26, 2026
- Transfer Order, In re: GLP-1 RAs Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, MDL No. 3163, Doc. 49 (J.P.M.L. filed Dec. 15, 2025)jpml.uscourts.gov · Last read Sept. 26, 2026
- Transfer Order, In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094, Doc. 272 (J.P.M.L. filed Dec. 12, 2024)jpml.uscourts.gov · Last read Sept. 26, 2026
GLP-1 litigation
22 documents · 107 records
- Amended Case Management Order No. 12 (Plaintiff Fact Sheets), No. 24-md-3094, Doc. 656 (E.D. Pa. filed Apr. 30, 2026)paed.uscourts.gov · Last read Sept. 25, 2026
- Case Management Order No. 6 (Science Day), No. 25-md-3163, Doc. 67 (E.D. Pa. filed Mar. 16, 2026)paed.uscourts.gov · Last read Sept. 25, 2026
- Case Management Order No. 12 (Cross Cutting Issues), No. 25-md-3163, Doc. 120 (E.D. Pa. filed July 2, 2026)paed.uscourts.gov · Last read Sept. 25, 2026
- Case Management Order No. 20, In re GLP-1 RAs Prods. Liab. Litig., No. 24-md-3094, Doc. 282 (E.D. Pa. filed Oct. 25, 2024)paed.uscourts.gov · Last read Sept. 25, 2026
- Case Management Order No. 25 (Coordination Order), No. 24-md-3094, Doc. 370 (E.D. Pa. filed Mar. 21, 2025)paed.uscourts.gov · Last read Sept. 25, 2026
- Case Management Order No. 27 (Short Form Complaint Enabling Order), No. 24-md-3094, Doc. 503 (E.D. Pa. filed Oct. 3, 2025)paed.uscourts.gov · Last read Sept. 25, 2026
- European Medicines Agency announcement, PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy (6 June 2025, revised 13 June 2025)ema.europa.eu · Last read Sept. 25, 2026
- Grauslund J, Taha AA, et al., Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes, Int J Retina Vitreous 2024;10(1):97 (PMID 39696569)pubmed.ncbi.nlm.nih.gov · Last read Sept. 25, 2026
- JPML, MDL Statistics Report - Distribution of Pending MDL Dockets by Actions Pending (report date Sept. 1, 2026)jpml.uscourts.gov · Last read Sept. 25, 2026
- Mounjaro prescribing information, DailyMed set id d2d7da5d-ad07-4228-955f-cf7e355c8cc0, SPL version 40 (published on DailyMed 2026-09-02), read Sept. 25, 2026dailymed.nlm.nih.gov · Last read Sept. 25, 2026
- Order (Scheduling Order - Rule 702 Evidentiary Hearing on Cross Cutting Issues 2 and 3), No. 24-md-3094, Doc. 881 (E.D. Pa. filed Aug. 28, 2026)paed.uscourts.gov · Last read Sept. 25, 2026
- Ozempic prescribing information, DailyMed set id adec4fd2-6858-4c99-91d4-531f5f2a2d79, SPL version 20 (published on DailyMed 2026-06-10), read Sept. 25, 2026dailymed.nlm.nih.gov · Last read Sept. 25, 2026
- Rybelsus prescribing information, DailyMed set id 27f15fac-7d98-4114-a2ec-92494a91da98, SPL version 14 (published on DailyMed 2026-08-19), read Sept. 25, 2026dailymed.nlm.nih.gov · Last read Sept. 25, 2026
- Saxenda prescribing information, DailyMed set id 3946d389-0926-4f77-a708-0acb8153b143, SPL version 22 (published on DailyMed 2026-06-15), read Sept. 25, 2026dailymed.nlm.nih.gov · Last read Sept. 25, 2026
- Transfer Order, In re: GLP-1 RAs Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, MDL No. 3163, Doc. 49 (J.P.M.L. filed Dec. 15, 2025)jpml.uscourts.gov · Last read Sept. 25, 2026
- Transfer Order, In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094, Doc. 145 (J.P.M.L. filed Feb. 2, 2024)jpml.uscourts.gov · Last read Sept. 25, 2026
- Trulicity prescribing information, DailyMed set id 463050bd-2b1c-40f5-b3c3-0a04bb433309, SPL version 62 (published on DailyMed 2026-08-10), read Sept. 25, 2026dailymed.nlm.nih.gov · Last read Sept. 25, 2026
- U.S. District Court for the Eastern District of Pennsylvania, MDL 3094 page, read Sept. 25, 2026paed.uscourts.gov · Last read Sept. 25, 2026
- U.S. District Court for the Eastern District of Pennsylvania, MDL 3163 page, read Sept. 25, 2026paed.uscourts.gov · Last read Sept. 25, 2026
- Vilsbøll T, Arun Kumar D, Aiello LP, Rönnbäck C, Stellfeld M, Larsen LM, Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide, Br J Ophthalmol, published online Apr. 28, 2026 (PMID 42049287)pubmed.ncbi.nlm.nih.gov · Last read Sept. 25, 2026
- Wegovy prescribing information, DailyMed set id ee06186f-2aa3-4990-a760-757579d8f77b, SPL version 19 (published on DailyMed 2026-06-30), read Sept. 25, 2026dailymed.nlm.nih.gov · Last read Sept. 25, 2026
- Zepbound prescribing information, DailyMed set id 487cd7e7-434c-4925-99fa-aa80b1cc776b, SPL version 40 (published on DailyMed 2026-09-02), read Sept. 25, 2026dailymed.nlm.nih.gov · Last read Sept. 25, 2026
GLP-1 drugs: other injuries
33 documents · 105 records
- Drug Safety Communications, the list served at this page, U.S. Food and Drug Administration, read Sept. 27, 2026fda.gov · Last read Sept. 27, 2026
- European Medicines Agency, Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024 (12 April 2024), read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- European Medicines Agency, Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 July 2024 (12 July 2024), read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- FDA Drug Safety Communication, FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications (dated 01-13-2026 on its page; content current as of 04/03/2026), U.S. Food and Drug Administration, read Sept. 27, 2026fda.gov · Last read Sept. 27, 2026
- FDA Drug Safety Communication, Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity (dated 01-11-2024 on its page; content current as of 04/03/2026), U.S. Food and Drug Administration, read Sept. 27, 2026fda.gov · Last read Sept. 27, 2026
- FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes [3-14-2013], U.S. Food and Drug Administration, read Sept. 27, 2026 from the Internet Archive capture of Dec. 24, 2024fda.gov · Last read Sept. 27, 2026
- July - September 2023 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) (content current as of 04/02/2026), U.S. Food and Drug Administration, read Sept. 27, 2026fda.gov · Last read Sept. 27, 2026
- Memorandum, In re GLP-1 RAs Prods. Liab. Litig., No. 24-md-3094, Doc. 276 (E.D. Pa. filed Oct. 17, 2024)govinfo.gov · Last read Sept. 27, 2026
- Memorandum, In re GLP-1 RAs Prods. Liab. Litig., No. 24-md-3094, Doc. 465 (E.D. Pa. filed Aug. 15, 2025)govinfo.gov · Last read Sept. 27, 2026
- Memorandum, In re GLP-1 RAs Prods. Liab. Litig., No. 24-md-3094, Doc. 467 (E.D. Pa. filed Aug. 15, 2025)govinfo.gov · Last read Sept. 27, 2026
- Mounjaro prescribing information, DailyMed set id d2d7da5d-ad07-4228-955f-cf7e355c8cc0, label revised 8/2026, read Sept. 27, 2026dailymed.nlm.nih.gov · Last read Sept. 27, 2026
- Mounjaro, EPAR product information, European Medicines Agency (product information last updated 21/09/2026, as printed on the EPAR page), read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- Mounjaro, European public assessment report (EPAR) page, European Medicines Agency, read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS), and the 23 quarterly pages it links, U.S. Food and Drug Administration, read Sept. 27, 2026fda.gov · Last read Sept. 27, 2026
- Ozempic prescribing information, DailyMed set id adec4fd2-6858-4c99-91d4-531f5f2a2d79, label revised 5/2026, read Sept. 27, 2026dailymed.nlm.nih.gov · Last read Sept. 27, 2026
- Ozempic, EPAR product information, European Medicines Agency (product information last updated 25/08/2026, as printed on the EPAR page), read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- Ozempic, European public assessment report (EPAR) page, European Medicines Agency, read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- Rybelsus and Ozempic tablets (one label) prescribing information, DailyMed set id 27f15fac-7d98-4114-a2ec-92494a91da98, label revised 1/2026, read Sept. 27, 2026dailymed.nlm.nih.gov · Last read Sept. 27, 2026
- Rybelsus, EPAR product information, European Medicines Agency (product information last updated 22/04/2026, as printed on the EPAR page), read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- Rybelsus, European public assessment report (EPAR) page, European Medicines Agency, read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- Saxenda prescribing information, DailyMed set id 3946d389-0926-4f77-a708-0acb8153b143, label revised 6/2026, read Sept. 27, 2026dailymed.nlm.nih.gov · Last read Sept. 27, 2026
- Saxenda, EPAR product information, European Medicines Agency (product information last updated 31/07/2025, as printed on the EPAR page), read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- Saxenda, European public assessment report (EPAR) page, European Medicines Agency, read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- Trulicity prescribing information, DailyMed set id 463050bd-2b1c-40f5-b3c3-0a04bb433309, label revised 3/2026, read Sept. 27, 2026dailymed.nlm.nih.gov · Last read Sept. 27, 2026
- Trulicity, EPAR product information, European Medicines Agency (product information last updated 30/01/2026, as printed on the EPAR page), read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- Trulicity, European public assessment report (EPAR) page, European Medicines Agency, read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- Victoza prescribing information, DailyMed set id 5a9ef4ea-c76a-4d34-a604-27c5b505f5a4, label revised 10/2025, read Sept. 27, 2026dailymed.nlm.nih.gov · Last read Sept. 27, 2026
- Victoza, EPAR product information, European Medicines Agency (product information last updated 20/02/2025, as printed on the EPAR page), read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- Victoza, European public assessment report (EPAR) page, European Medicines Agency, read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- Wegovy prescribing information, DailyMed set id ee06186f-2aa3-4990-a760-757579d8f77b, label revised 6/2026, read Sept. 27, 2026dailymed.nlm.nih.gov · Last read Sept. 27, 2026
- Wegovy, EPAR product information, European Medicines Agency (product information last updated 21/09/2026, as printed on the EPAR page), read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- Wegovy, European public assessment report (EPAR) page, European Medicines Agency, read Sept. 27, 2026ema.europa.eu · Last read Sept. 27, 2026
- Zepbound prescribing information, DailyMed set id 487cd7e7-434c-4925-99fa-aa80b1cc776b, label revised 8/2026, read Sept. 27, 2026dailymed.nlm.nih.gov · Last read Sept. 27, 2026
Asbestos bankruptcy trusts
5 documents · 21 records
- 11 U.S.C. § 524(g)(5)govinfo.gov · Last read Oct. 6, 2026
- Owens Corning/Fibreboard Asbestos PI Trust Distribution Procedures § 2.3 (rev. Dec. 2, 2015)ocfbasbestostrust.com · Last read Oct. 6, 2026
- Owens Corning/Fibreboard Asbestos PI Trust, ER Settlement (read Oct. 6, 2026)ocfbasbestostrust.com · Last read Oct. 6, 2026
- Owens Corning/Fibreboard Asbestos PI Trust, Fibreboard Sub-Account payment percentage notice (June 30, 2026)ocfbasbestostrust.com · Last read Oct. 6, 2026
- Owens Corning/Fibreboard Asbestos PI Trust, Owens Corning Sub-Account payment percentage notice (June 30, 2026)ocfbasbestostrust.com · Last read Oct. 6, 2026
Drug injury filing deadlines by state
84 documents · 337 records
- 10 Del. C. § 8119delcode.delaware.gov · Last read Sept. 27, 2026
- 12 Okla. Stat. § 95(A)oscn.net · Last read Sept. 27, 2026
- 12 V.S.A. § 512legislature.vermont.gov · Last read Sept. 27, 2026
- 14 M.R.S. § 752legislature.maine.gov · Last read Sept. 27, 2026
- 42 Pa.C.S. § 5524legis.state.pa.us · Last read Sept. 27, 2026
- 735 ILCS 5/13-202ilga.gov · Last read Sept. 27, 2026
- 735 ILCS 5/13-213ilga.gov · Last read Sept. 27, 2026
- A.R.S. § 12-542(1)azleg.gov · Last read Sept. 27, 2026
- A.R.S. § 12-551azleg.gov · Last read Sept. 27, 2026
- Ala. Code § 6-2-38(l)alison.legislature.state.al.us · Last read Sept. 27, 2026
- Ala. Code § 6-5-502(a)alison.legislature.state.al.us · Last read Sept. 27, 2026
- Alaska Stat. § 09.10.070(a)akleg.gov · Last read Sept. 27, 2026
- Bank of the Ozarks, Inc. v. Ford Motor Co., 2020 Ark. App. 231, No. CV-19-665 (Ark. Ct. App. Apr. 15, 2020), n.2opinions.arcourts.gov · Last read Sept. 27, 2026
- Buechel v. Five Star Quality Care, Inc., No. 06-1239 (Iowa filed Mar. 7, 2008)iowacourts.gov · Last read Sept. 27, 2026
- Burroughs v. Strength of Nature Global, LLC, 322 Ga. 722, Nos. S24G1387, S24G1388 (Ga. decided Oct. 15, 2025)gasupreme.us · Last read Sept. 27, 2026
- Cal. Civ. Proc. Code § 335.1leginfo.legislature.ca.gov · Last read Sept. 27, 2026
- Cal. Civ. Proc. Code § 340.8(a)leginfo.legislature.ca.gov · Last read Sept. 27, 2026
- Colo. Rev. Stat. § 13-80-106(1) (2024)content.leg.colorado.gov · Last read Sept. 27, 2026
- Conn. Gen. Stat. § 52-584cga.ct.gov · Last read Sept. 27, 2026
- D.C. Code § 12-301code.dccouncil.gov · Last read Sept. 27, 2026
- D.M.S. v. Barber, No. C8-00-2227 (Minn. June 13, 2002)lawlibrary.state.mn.us · Last read Sept. 27, 2026
- Fla. Stat. § 95.11(5)leg.state.fl.us · Last read Sept. 27, 2026
- Fla. Stat. § 95.031(1)leg.state.fl.us · Last read Sept. 27, 2026
- Fox v. Ethicon Endo-Surgery, Inc., 35 Cal.4th 797, No. S121173 (Cal. filed May 9, 2005)courtinfo.ca.gov · Last read Sept. 27, 2026
- Haw. Rev. Stat. § 657-7capitol.hawaii.gov · Last read Sept. 27, 2026
- Idaho Code § 5-219legislature.idaho.gov · Last read Sept. 27, 2026
- Idaho Code § 6-1403(3)legislature.idaho.gov · Last read Sept. 27, 2026
- Ind. Code § 34-11-2-4(a)iga.in.gov · Last read Sept. 27, 2026
- Iowa Code § 614.1legis.iowa.gov · Last read Sept. 27, 2026
- K.S.A. 60-513(a)ksrevisor.gov · Last read Sept. 27, 2026
- KRS 413.140(1)apps.legislature.ky.gov · Last read Sept. 27, 2026
- La. Civ. Code art. 3492legis.la.gov · Last read Sept. 27, 2026
- La. Civ. Code art. 3493.1legis.la.gov · Last read Sept. 27, 2026
- Martin v. Arthur, 339 Ark. 149, 3 S.W.3d 684, No. 99-302 (Ark. Nov. 11, 1999)opinions.arcourts.gov · Last read Sept. 27, 2026
- Mass. Gen. Laws ch. 106, § 2-318malegislature.gov · Last read Sept. 27, 2026
- Mass. Gen. Laws ch. 260, § 2Amalegislature.gov · Last read Sept. 27, 2026
- MCL 600.5805(2)legislature.mi.gov · Last read Sept. 27, 2026
- MCL 600.5827legislature.mi.gov · Last read Sept. 27, 2026
- Md. Code, Cts. & Jud. Proc. § 5-101mgaleg.maryland.gov · Last read Sept. 27, 2026
- Minn. Stat. § 541.05, subd. 1revisor.mn.gov · Last read Sept. 27, 2026
- Minn. Stat. § 541.07revisor.mn.gov · Last read Sept. 27, 2026
- Mo. Rev. Stat. § 516.100revisor.mo.gov · Last read Sept. 27, 2026
- Mo. Rev. Stat. § 516.120revisor.mo.gov · Last read Sept. 27, 2026
- Mont. Code Ann. § 27-2-102(2)mca.legmt.gov · Last read Sept. 27, 2026
- Mont. Code Ann. § 27-2-204(1) (temporary)mca.legmt.gov · Last read Sept. 27, 2026
- Morietta v. Reese Construction Co., No. 5-03-0215 (Ill. App. Ct. 5th Dist., order filed Mar. 25, 2004; published Apr. 22, 2004)illinoiscourts.gov · Last read Sept. 27, 2026
- N.C. Gen. Stat. § 1-46.1(1)ncleg.gov · Last read Sept. 27, 2026
- N.C. Gen. Stat. § 1-52ncleg.gov · Last read Sept. 27, 2026
- N.D.C.C. § 28-01-16ndlegis.gov · Last read Sept. 27, 2026
- N.D.C.C. § 28-01.3-08(1)ndlegis.gov · Last read Sept. 27, 2026
- N.H. Rev. Stat. § 507-D:2, Igencourt.state.nh.us · Last read Sept. 27, 2026
- N.H. Rev. Stat. § 508:4, Igc.nh.gov · Last read Sept. 27, 2026
- N.J.S.A. 2A:14-2alis.njleg.state.nj.us · Last read Sept. 27, 2026
- N.M. Stat. § 37-1-8nmonesource.com · Last read Sept. 27, 2026
- N.Y. C.P.L.R. 214nysenate.gov · Last read Sept. 27, 2026
- N.Y. C.P.L.R. 214-c(2)nysenate.gov · Last read Sept. 27, 2026
- Neb. Rev. Stat. § 25-207nebraskalegislature.gov · Last read Sept. 27, 2026
- Neb. Rev. Stat. § 25-224(1)nebraskalegislature.gov · Last read Sept. 27, 2026
- NRS 11.190(4)leg.state.nv.us · Last read Sept. 27, 2026
- Ohio Rev. Code § 2305.10(A)codes.ohio.gov · Last read Sept. 27, 2026
- Or. Rev. Stat. § 12.110(1)oregonlegislature.gov · Last read Sept. 27, 2026
- Or. Rev. Stat. § 30.905(1)oregonlegislature.gov · Last read Sept. 27, 2026
- Pflanz v. Foster, No. 36S01-0710-CV-425 (Ind. June 19, 2008)in.gov · Last read Sept. 27, 2026
- Provisions read for this page: the Mississippi Code, which could not be readlegislature.ms.gov · Last read Sept. 27, 2026
- R.I. Gen. Laws § 9-1-13(b)webserver.rilegislature.gov · Last read Sept. 27, 2026
- R.I. Gen. Laws § 9-1-14(b)webserver.rilegislature.gov · Last read Sept. 27, 2026
- RCW 4.16.080app.leg.wa.gov · Last read Sept. 27, 2026
- RCW 7.72.060(3)app.leg.wa.gov · Last read Sept. 27, 2026
- S.C. Code § 15-3-530scstatehouse.gov · Last read Sept. 27, 2026
- S.D. Codified Laws § 15-2-12.2sdlegislature.gov · Last read Sept. 27, 2026
- S.D. Codified Laws § 15-2-14sdlegislature.gov · Last read Sept. 27, 2026
- Santos v. George Washington University Hospital, No. 07-CV-992 (D.C. decided Sept. 3, 2009)dccourts.gov · Last read Sept. 27, 2026
- Sipe v. STS Manufacturing, Inc., No. A11-2082 (Minn. July 31, 2013)mn.gov · Last read Sept. 27, 2026
- Tenn. Code Ann. § 28-3-104(a)(1)(A)lexisnexis.com · Last read Sept. 27, 2026
- Tex. Civ. Prac. & Rem. Code § 16.003(a)statutes.capitol.texas.gov · Last read Sept. 27, 2026
- Utah Code § 78B-6-703(1)le.utah.gov · Last read Sept. 27, 2026
- Utah Code § 78B-6-706le.utah.gov · Last read Sept. 27, 2026
- Va. Code § 8.01-230law.lis.virginia.gov · Last read Sept. 27, 2026
- Va. Code § 8.01-243(A)law.lis.virginia.gov · Last read Sept. 27, 2026
- Va. Code § 8.01-249(4a)law.lis.virginia.gov · Last read Sept. 27, 2026
- W. Va. Code § 55-2-12code.wvlegislature.gov · Last read Sept. 27, 2026
- Wis. Stat. § 893.54(1m)(a)docs.legis.wisconsin.gov · Last read Sept. 27, 2026
- Wis. Stat. § 895.047(5)docs.legis.wisconsin.gov · Last read Sept. 27, 2026
- Wyo. Stat. § 1-3-105(a)wyoleg.gov · Last read Sept. 27, 2026